{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:54:26Z","timestamp":1770465266428,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.euo.2024.04.014","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T06:16:05Z","timestamp":1715408165000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial"],"prefix":"10.1016","volume":"8","author":[{"given":"Loic","family":"Ah-Thiane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loic","family":"Campion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nedjla","family":"Allouache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Mesgouez-Nebout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Agathe","family":"Serre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Guimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Rio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Mahier Ait Oukhatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-1708","authenticated-orcid":false,"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.04.014_b0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2021.07.027","article-title":"Risk stratification of patients candidate to radical prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: development and external validation of novel risk groups","volume":"81","author":"Mazzone","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.04.014_b0010","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.juro.2009.08.027","article-title":"Radiation therapy after radical prostatectomy: impact on metastasis and survival","volume":"182","author":"Boorjian","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.04.014_b0015","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2024.04.014_b0020","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.eururo.2019.11.023","article-title":"Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, phase 3 trial (JCOG0401)","volume":"77","author":"Yokomizo","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.04.014_b0025","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0022-5347(05)67817-2","article-title":"Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer","volume":"163","author":"Pisansky","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.04.014_b0030","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0035","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 randomized phase 3 trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.04.014_b0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijrobp.2019.09.047","article-title":"Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: results of a randomized phase III trial","volume":"106","author":"Qi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.04.014_b0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.04.014_b0050","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0055","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"suppl_7","key":"10.1016\/j.euo.2024.04.014_b0060","first-page":"S808","article-title":"LBA9\u2014Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031)","volume":"33","author":"Parker","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0065","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.04.014_b0070","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.04.014_b0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.04.014_b0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.04.014_b0085","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.04.014_b0090","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.04.014_b0095","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.04.014_b0100","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1878-0261.12869","article-title":"Clinical utility of circulating tumor cells: an update","volume":"15","author":"Vasseur","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0105","doi-asserted-by":"crossref","first-page":"22147","DOI":"10.18632\/oncotarget.25189","article-title":"Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: a phase I study of the GETUG\/GEP","volume":"9","author":"Supiot","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2024.04.014_b0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"10.1016\/j.euo.2024.04.014_b0115","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.euo.2024.04.014_b0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11864-004-0026-2","article-title":"Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy","volume":"5","author":"Stephenson","year":"2004","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clon.2008.02.008","article-title":"Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies","volume":"20","author":"Hudson","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.euo.2024.04.014_b0130","doi-asserted-by":"crossref","first-page":"e103574","DOI":"10.1371\/journal.pone.0103574","article-title":"Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes","volume":"9","author":"Kwon","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2024.04.014_b0135","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.eururo.2013.08.013","article-title":"Early salvage radiotherapy following radical prostatectomy","volume":"65","author":"Pfister","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.04.014_b0140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euros.2021.09.015","article-title":"Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy","volume":"34","author":"Autio","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.04.014_b0145","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2020.11.059","article-title":"Combination of radiation therapy and short-term androgen blockade with abiraterone acetate plus prednisone for men with high- and intermediate-risk localized prostate cancer","volume":"109","author":"Koontz","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.04.014_b0150","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","article-title":"Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer","volume":"28","author":"Franke","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0155","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jhep.2007.06.022","article-title":"Interferon-gamma exacerbates liver damage, the hepatic progenitor cell response and fibrosis in a mouse model of chronic liver injury","volume":"47","author":"Knight","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.euo.2024.04.014_b0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1667\/RR14072.1","article-title":"Localized external beam radiation therapy (EBRT) to the pelvis induces systemic IL-1beta and TNF-alpha production: role of the TNF-alpha signaling in EBRT-induced fatigue","volume":"185","author":"McDonald","year":"2016","journal-title":"Radiat Res"},{"key":"10.1016\/j.euo.2024.04.014_b0165","doi-asserted-by":"crossref","first-page":"G583","DOI":"10.1152\/ajpgi.00422.2005","article-title":"Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways","volume":"290","author":"Schwabe","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.euo.2024.04.014_b0170","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/1078-0432.CCR-09-0245","article-title":"Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity","volume":"15","author":"Christensen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.04.014_b0175","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.euo.2020.01.005","article-title":"Phase II trial of enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: the STREAM trial","volume":"4","author":"Bitting","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0180","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12885-019-5805-z","article-title":"A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)","volume":"19","author":"Kapoor","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2024.04.014_b0185","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2024.04.014_b0190","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2023.41.6_suppl.303","article-title":"FORMULA-509: a multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate\/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)","volume":"41","author":"Nguyen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102626","article-title":"Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)","volume":"120","author":"Ah-Thiane","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2024.04.014_b0200","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials","volume":"36","author":"Heller","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.04.014_b0205","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/j.clgc.2015.04.003","article-title":"Circulating tumor cells in biochemical recurrence of prostate cancer","volume":"13","author":"Aragon-Ching","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2024.04.014_b0210","first-page":"2975","article-title":"Analysis of circulating tumor cells in prostate cancer patients at PSA recurrence and review of the literature","volume":"36","author":"Grisanti","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2024.04.014_b0215","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/pcan.2015.36","article-title":"The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy","volume":"18","author":"Lowes","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2024.04.014_b0220","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13073-020-00770-1","article-title":"Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression","volume":"12","author":"Lau","year":"2020","journal-title":"Genome Med"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T21:42:23Z","timestamp":1739223743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2588931124001081"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.04.014","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}